Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antipsychotic medications, each with different receptor binding profiles. Olanzapine is an atypical antipsychotic with stronger affinity for serotonin 5-HT2 receptors than dopamine D2 receptors[1][4]. Risperidone is another atypical antipsychotic that works by balancing dopamine and serotonin levels in the brain[10]. Sulpiride is a selective D2 antagonist that can enhance D2 blockade when combined with other antipsychotics[1][4].\n\nThe rationale behind combining these medications is to leverage their different receptor affinities to potentially enhance clinical efficacy in treatment-resistant schizophrenia[1][2]. While the search results don't specifically discuss the triple combination of all three drugs together, they do provide information about various dual combinations of these and similar antipsychotics.\n\nThe search results indicate that combinations of atypical antipsychotics are generally well-tolerated and may be effective for managing treatment-refractory schizophrenia[2]. Specific combinations mentioned include:\n\n- Olanzapine + sulpiride: A preliminary study showed noteworthy and rapid clinical improvement in six patients with chronic schizophrenia, supported by decreased scores on the Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale, with no bothersome side effects reported[1][4].\n\n- Clozapine + sulpiride: A Cochrane review found this combination more effective than clozapine alone, though more data was needed for firm conclusions[9].\n\n- Clozapine + risperidone: Studies showed mixed results, with one double-blind RCT showing significantly superior improvement of positive, negative, and total psychopathology, while another RCT revealed significantly inferior improvement of positive symptoms compared to placebo[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Olanzapine, Risperidone, and Sulpiride Combination.